Stereotactic Radiosurgery for Intramedullary Spinal Cord Metastases: A Systematic Review and Meta-Analysis

立体定向放射外科治疗髓内脊髓转移瘤:系统评价和荟萃分析

阅读:1

Abstract

Intramedullary spinal cord metastases (ISCM) represent a rare but increasingly diagnosed cancer dissemination. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiosurgery (FSRS) have emerged as a local treatment option in this context over recent years. This systematic review and meta-analysis aim to assess the safety and effectiveness of SRS/FSRS in ISCM. A systematic literature review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching in PubMed/MEDLINE and Google Scholar databases. Studies were selected based on predefined criteria, with bias risk evaluated using Joanna Briggs Institute (JBI) tools. Relevant data were extracted for subsequent meta-analysis. Descriptive statistics and survival analysis using Kaplan-Meier were performed. Ten studies including 60 patients and 77 ISCM treated with SRS/FSRS were selected. The median age was 50 years, with a female predominance (70%). Breast cancer was the most common metastatic origin (41.7%). Kaplan-Meier analysis in 27 patients showed an estimated overall survival (OS) at 12 months of 35.33% (95% CI 0.18-0.53) and at 24 months of 25.98% (95% CI 0.11-0.44), with a median OS of nine months (95% CI 5.2-14). Local control was achieved in 86.3% at the end of follow-up, with favorable neurological control in 69% of patients and no spinal cord toxicity. The findings of this systematic review and meta-analysis suggest that SRS/FSRS appears to be safe and effective in treating ISCM. However, given the low quality of the included studies, these results should be interpreted with caution. Prospective studies are needed to better define the role of SRS/FSRS and evaluate spinal toxicity in this context.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。